CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $)	12 Months Ended
	Sep. 30, 2012	Sep. 30, 2011
Cash flows from operating activities:
Net income (loss)	$ (4,303,766)	$ 1,351,645
Adjustments to reconcile net income (loss) to net cash provided by operating activities:
Stock compensation expense	935,396	563,443
Foreign exchange loss	30,602	0
Contingent consideration adjustment	(17,376)	(95,887)
Depreciation and Amortization	1,669,719	1,233,073
Noncash interest expense	41,799	39,912
Provision for doubtful accounts and sales returns	0	26,110
Inventory reserves	76,981	0
Deferred income taxes	166,920	128,471
Impairment of goodwill	2,284,499	0
(Increase) decrease in:
Accounts receivable, net	(2,107,477)	497,337
Costs in excess of billings	1,121,344	(273,083)
Inventories	(134,449)	(153,320)
Prepaid expenses and other current assets	(574,652)	(175,914)
Increase (decrease) in:
Accounts payable	338,205	151,238
Accrued expenses and other liabilities	470,637	599,621
Deferred revenue	694,672	0
Net cash provided by operating activities	741,915	3,892,646
Cash flows from investing activities:
Purchases of property, plant and equipment	(1,018,213)	(1,543,262)
Cash paid for acquisition of Biomedical Technologies	0	(300,000)
Net cash used in investing activities	(1,018,213)	(1,843,262)
Cash flows from financing activities:
Proceeds from issuance of common stock	63,122	135,302
Payment of debt issuance costs	(56,600)	0
Repayment of long-term debt	(1,860,678)	(1,858,943)
Proceeds from long term debt	3,000,000	0
Buy back of common stock	(1,857,546)	0
Preferred stock dividends paid	0	(79,770)
Net cash used in financing activities	(711,702)	(1,803,411)
Effect of exchange rates on cash and cash equivalents	(28,099)	121,901
Net change in cash and cash equivalents	(1,064,960)	367,874
Cash and cash equivalents, beginning	4,479,840	4,111,966
Cash and cash equivalents, ending	$ 3,414,880	$ 4,479,840